Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 916 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: End-of-Life Clear all
Terminated Not applicable Interventional

Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life

NCT02652676
View directory record Official record
Conditions
Acute on Chronic Systolic Congestive Heart Failure
Interventions
Reversible Pulmonary Artery Banding, GORE-TEX DualMesh EMERGE PLUS Biomaterial
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
Up to 4 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Jun 26, 2026, 3:23 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
BNT116, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

NCT01776424
View directory record Official record
Conditions
Prevention & Control
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
27,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death

NCT00993382
View directory record Official record
Conditions
Arrhythmia Prophylaxis, Ventricular Arrhythmia
Interventions
Celivarone, Amiodarone, Matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
37
States / cities
Huntsville, Alabama • Mobile, Alabama • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

NCT01598987
View directory record Official record
Conditions
Renal Function, Liver Transplant
Interventions
Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Mediating Effects of Decentering on Self-Management of Stress and End of Life Planning

NCT02842047
View directory record Official record
Conditions
Stage IV Gastrointestinal Cancer, Advanced Gynecological Cancer
Interventions
Stop, Breathe & Think™, End of Life Planning Videos, Caregiver wellness videos
Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

NCT01178216
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Rituxan
Biological
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Phase 4 Interventional Results available

Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial

NCT05322252
View directory record Official record
Conditions
Abortion, Second Trimester, PPROM, Rupture, Spontaneous, Fetal Demise, Fetal Death, Fetal Demise From Miscarriage, Fetal Death Before 22 Weeks With Retention of Dead Fetus, Pregnancy Loss, Pregnancy Complications
Interventions
Mifepristone, Misoprostol
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 26, 2026, 3:23 PM EDT
Completed No phase listed Observational

Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer

NCT00414492
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Not listed
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2010 · Synced Jun 26, 2026, 3:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions
BNT323, BNT327
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jun 26, 2026, 3:23 PM EDT
Completed No phase listed Observational

A Study of Potential Treatment-Responsive Biomarkers and Clinical Outcomes in Hunter Syndrome

NCT04007536
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
No Intervention
Other
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
Up to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Oakland, California • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2024 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Not applicable Interventional

Coaches Activating Reaching and Engaging Patients

NCT03856463
View directory record Official record
Conditions
Cancer, End-of-Life
Interventions
Lay Navigator Intervention, Usual Care
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Jun 26, 2026, 3:23 PM EDT
Enrolling by invitation No phase listed Observational

IVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry

NCT04520347
View directory record Official record
Conditions
Ventricular Arrhythmia, Ventricular Tachycardia, Premature Ventricular Contraction (PVC), Cardiomyopathy
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jun 26, 2026, 3:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

NCT02205333
View directory record Official record
Conditions
Advanced Solid Tumors, Aggressive B-cell Lymphomas
Interventions
MEDI6469 Monotherapy, MEDI6469 Plus Tremelimumab, MEDI6469 Plus Durvalumab, MEDI6469 plus Rituximab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Variable Dead Space Rebreathing Device to Treat Sleep Apnea

NCT03552133
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Sleep Apnea, Central
Interventions
Smart CO2
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

NCT03095352
View directory record Official record
Conditions
Breast Cancer, Chest Wall Disease
Interventions
Pembrolizumab, Carboplatin, Trastuzumab
Biological · Drug
Lead sponsor
Laura Huppert, MD, BA
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Vitamin D for COVID-19 Trial

NCT04536298
View directory record Official record
Conditions
COVID-19
Interventions
vitamin D, Placebo
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,024 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Not applicable Interventional

Heart Transplantation Using Normothermic Regional Perfusion Donation After Circulatory Death

NCT04284319
View directory record Official record
Conditions
Heart Failure
Interventions
DCD Heart Transplantation Using NRP
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jun 26, 2026, 3:23 PM EDT
Active, not recruiting No phase listed Observational

International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

NCT04496687
View directory record Official record
Conditions
Spontaneous Coronary Artery Dissection
Interventions
Not listed
Lead sponsor
SCAD Alliance
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 26, 2026, 3:23 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Preeclampsia Registry

NCT06377878
View directory record Official record
Conditions
Preeclampsia, Eclampsia, HELLP Syndrome, Toxemia, Hypertensive Disorder of Pregnancy
Interventions
Not listed
Lead sponsor
Preeclampsia Foundation
Other
Eligibility
13 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2040
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Jun 26, 2026, 3:23 PM EDT
Recruiting No phase listed Observational

Longitudinal Study of Neurodegenerative Disorders

NCT03333200
View directory record Official record
Conditions
MLD, Krabbe Disease, ALD, MPS I, MPS II, MPS III, Vanishing White Matter Disease, GM3 Gangliosidosis, PKAN, Tay-Sachs Disease, NP Deficiency, Osteopetrosis, Alpha-Mannosidosis, Sandhoff Disease, Niemann-Pick Diseases, MPS IV, Gaucher Disease, GAN, GM1 Gangliosidoses, Morquio Disease, S-Adenosylhomocysteine Hydrolase Deficiency, Batten Disease, Pelizaeus-Merzbacher Disease, Leukodystrophy, Lysosomal Storage Diseases, Purine Nucleoside Phosphorylase Deficiency, Multiple Sulfatase Deficiency Disease
Interventions
Palliative Care, Hematopoetic Stem Cell Transplantation
Other · Biological
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2035
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jun 26, 2026, 3:23 PM EDT
Completed No phase listed Observational Results available

Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

NCT02127307
View directory record Official record
Conditions
Heart Failure (HF)
Interventions
Not listed
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Jun 26, 2026, 3:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013)

NCT04521621
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
Gebasaxturev, Pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Hackensack, New Jersey • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jun 26, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Intervention to Improve End of Life Decision Making Among Homeless Persons

NCT00471016
View directory record Official record
Conditions
End of Life Decision Making, Advance Care Planning
Interventions
Guided intervention
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Jun 26, 2026, 3:23 PM EDT